Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Tuberculosis is a global health problem. The Mycobacterium bovis Bacille Calmette Guerin (BCG) vaccine has variable efficacy (0-80%) so there is a drive to develop novel vaccines. The cytokine, interferon gamma (IFNγ), is an essential component of the protective response to M. tuberculosis (M. tb) infection and is also produced in response to BCG vaccination. Induction of an IFNγ response is used as a biomarker of successful vaccination in the assessment of new tuberculosis (TB) vaccines. The IFNγ ELISPOT assay provides an important tool for TB research. It is used for both the diagnosis of infection (T.Spot assay), and for the evaluation of the immunogenicity of new TB vaccine candidates in human clinical trials, in the non-human primate (NHP) model of TB infection studies. The ELISPOT assay captures IFNγ produced by peripheral blood mononuclear cells (PBMCs) following specific stimulation, onto a membrane so individual cells can be enumerated and the frequency of responding cells determined. Hence spot forming units (SFU) per 106 cells provide the traditional measure for ELISPOT assays. The discriminatory power of SFU is limited. In some situations, the number of SFU in BCG vaccinated, and unvaccinated, subjects was found to be similar, although the spots were observed to be larger in vaccinated subjects. Spot size potentially provides a measure of the quantity of cytokine produced by individual cells. The AID ELISPOT plate reader software used to determine frequency of spots also has the capability to determine the size of each spot. Consideration of spot size in combination with spot forming units was investigated in our studies of BCG immunogenicity. This additional readout was found to enhance the discriminatory power of the ELISPOT assay, and provide more information on the immune response to BCG vaccination and infection with M.tb.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3972643 | PMC |
| http://dx.doi.org/10.3390/cells1010005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of cytomegalovirus cell-mediated immunity assays in the healthy Singapore cohort and challenges of test validation.
J Clin Virol
August 2025
Department of Microbiology, Singapore General Hospital, Singapore; SingHealth Duke-NUS Pathology Academic Clinical Programme, Singapore. Electronic address:
Background: Cytomegalovirus (CMV) is a major cause of morbidity and mortality for transplant and immunocompromised patients. While cell-mediated immunity (CMI) is crucial for control of CMV and can influence the management of patients, commercial kits to measure CMI responses have only recently become available. In this study, we evaluated 2 different test kit platforms to determine their performance with the aim of implementing CMV-CMI testing to serve local needs.
View Article and Find Full Text PDFCellular Immunogenicity Assessments in CAR-T Cell Therapies: Current Insights and Future Directions.
AAPS J
September 2025
Precision Medicine Bioanalytical & Translational Sciences, Bristol Myers Squibb, Route 206 & Province Line Road, Princeton, NJ, 08543, USA.
CAR-T-cells can drive MHC class-I-mediated CD8 + cytotoxic T-cell response towards CAR constructs in addition to an antibody response. Immune response may also develop towards residuals present in the CAR-T cell product such as AAV, CRISPR/CAS9, and expamers. Health authorities recommend developing assays to assess both humoral and cellular immunogenicity towards the CAR-T protein.
View Article and Find Full Text PDFThird exposure to COVID-19 infection or vaccination differentially impacts T cell responses.
J Infect
August 2025
The Francis Crick Institute, NW1 1AT London, UK; National Institute for Health Research (NIHR) University CollegeLondon Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, UK; Research Department of Infection, Division of Infection and Immunity, University College
Background: In 2021, the rapid rollout of two doses of SARS-CoV-2 vaccines reduced COVID-19 severity and mortality. However, further vaccine doses as a prime-boost schedule were limited, and lifting of public health restrictions by late 2021 frequently led to infection, rather than vaccine, as a third exposure.
Objective: To compare how the third exposure through mRNA booster or SARS-CoV-2 infection shapes humoral and cellular immunity following two vaccine doses.
Accelerating Neoantigen Discovery: A High-Throughput Approach to Immunogenic Target Identification.
Vaccines (Basel)
August 2025
myNEO Therapeutics, 9000 Ghent, Belgium.
: Antigen-targeting immunotherapies hinge on the accurate identification of immunogenic epitopes that elicit robust T-cell responses. However, current computational approaches focus primarily on MHC binding affinity, leading to high false-positive rates and limiting the clinical utility of antigen selection methods. : We developed the neoIM (for "neoantigen immunogenicity") model, a first-in-class, high-precision immunogenicity prediction tool that overcomes these limitations by focusing exclusively on overall CD8 T-cell response rather than MHC binding.
View Article and Find Full Text PDFVVX001 Induces preS-Specific Antibodies Reacting to Common HBV Genotypes in Hepatitis B Virus (HBV) Carrier Mice.
Vaccines (Basel)
August 2025
Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090 Vienna, Austria.
: Chronic hepatitis B (CHB) remains being a major public health threat, and currently existing CHB therapies have limited efficacy and side effects. We have recently developed a vaccine termed VVX001 based on a recombinant fusion protein consisting of the preS domain of the large surface protein of hepatitis B virus (HBV) fused to grass pollen allergen peptides. VVX001 has been shown to induce preS-specific antibodies in grass pollen allergic patients, and sera of immunized subjects inhibited HBV infection in vitro.
View Article and Find Full Text PDF